$0.65 EPS Expected for Abbott Laboratories (ABT)

September 17, 2017 - By Marie Mckinney

 $0.65 EPS Expected for Abbott Laboratories (ABT)
Investors sentiment increased to 1.01 in Q4 2016. Its up 0.05, from 0.96 in 2016Q3. It is positive, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported.
Essex Financial Svcs holds 0.26% or 31,295 shares in its portfolio. Fukoku Mutual Life Insur accumulated 9,600 shares. First Natl Bank & Tru Company Of Newtown stated it has 0.21% in Abbott Laboratories (NYSE:ABT). Hartford Investment Management has 419,816 shares for 0.3% of their portfolio. Argyle Cap, Pennsylvania-based fund reported 15,848 shares. Moreover, Thomaspartners has 1.93% invested in Abbott Laboratories (NYSE:ABT). The Wisconsin-based Provident has invested 0.04% in Abbott Laboratories (NYSE:ABT). State Street has invested 0.24% in Abbott Laboratories (NYSE:ABT). Indiana Trust & Investment Mgmt owns 18,806 shares. Martingale Asset Limited Partnership owns 9,262 shares. X Mngmt Commerce Ltd Com stated it has 0.01% in Abbott Laboratories (NYSE:ABT). Cubist Systematic Strategies Limited Liability Company has 0.12% invested in Abbott Laboratories (NYSE:ABT). Livforsakringsbolaget Skandia Omsesidigt has 123,917 shares for 0.24% of their portfolio. Mcrae Mngmt invested in 10,504 shares or 0.18% of the stock. 316 are held by Macroview Inv Mgmt Ltd Llc.

Since March 31, 2017, it had 0 insider purchases, and 2 insider sales for $60,722 activity. 767 shares were sold by Contreras Jaime, worth $34,240 on Friday, March 31.

Analysts await Abbott Laboratories (NYSE:ABT) to report earnings on October, 18. They expect $0.65 earnings per share, up 10.17 % or $0.06 from last year’s $0.59 per share. ABT’s profit will be $1.13 billion for 19.91 P/E if the $0.65 EPS becomes a reality. After $0.62 actual earnings per share reported by Abbott Laboratories for the previous quarter, Wall Street now forecasts 4.84 % EPS growth. The stock increased 0.12% or $0.06 on September 15, reaching $51.76. About 6.70M shares traded or 45.02% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since September 17, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 23 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 9 Hold. Therefore 61% are positive. Abbott Laboratories had 70 analyst reports since July 24, 2015 according to SRatingsIntel. Argus Research maintained the shares of ABT in report on Friday, July 21 with “Buy” rating. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Deutsche Bank on Saturday, August 29. Morgan Stanley maintained Abbott Laboratories (NYSE:ABT) rating on Tuesday, July 11. Morgan Stanley has “Equal-Weight” rating and $4 target. The rating was maintained by Jefferies with “Buy” on Thursday, July 14. BMO Capital Markets maintained it with “Hold” rating and $53.0 target in Thursday, August 31 report. On Thursday, August 27 the stock rating was maintained by Wells Fargo with “Buy”. As per Friday, February 5, the company rating was upgraded by Argus Research. Jefferies maintained the shares of ABT in report on Friday, June 16 with “Buy” rating. The stock of Abbott Laboratories (NYSE:ABT) earned “Buy” rating by Jefferies on Tuesday, September 5. On Tuesday, June 14 the stock rating was maintained by Jefferies with “Buy”.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $89.93 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 79.47 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Thestreet.com which released: “Alibaba, Qorvo, Abbott Laboratories, Square: ‘Mad Money’ Lightning Round” on September 16, 2017, also Nasdaq.com with their article: “Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?” published on August 21, 2017, Seekingalpha.com published: “Can Abbott Top Its All-Time High?” on September 07, 2017. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Investorplace.com and their article: “3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and …” published on September 12, 2017 as well as Chicagotribune.com‘s news article titled: “Abbott releases software fixes for heart devices that could be hacked” with publication date: August 30, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.